0 items USD 0.00Pharmaceutical Contract Manufacturing: 麻豆原创 Status and Leading Players
Contract Manufacturing or Third-Party Manufacturing is the lifeblood of the pharmaceutical industry. The Pharma industry has witnessed tremendous growth in recent years due to the production on a large scale which is only possible through Contract Manufacturing.
What is听Pharmaceutical Contract Manufacturing?
Pharmaceutical Contract Manufacturing refers to the process in which a pharmaceutical company hires a contractor for the manufacturing of drugs according to their specifications and formulas. Pharma Contract Manufacturing is a model adopted by companies ranging from small-scale to large-scale industries.听Other than Pharmaceutical, contract manufacturing is popular among Aerospace, Personal Care, and Automobile industries.
听
Under contract manufacturing, a pharma company owns听a large-scale production capacity to produce drugs for the third party. Through contract manufacturing companies can optimally use their production capacity. When the production is not fully utilized then pharma manufacturer looks for companies who wish to outsource their production.
What are the main features of Pharmaceutical Contract Manufacturing?
- A contract manufacturer usually produces for multiple customers as he can buy raw materials in bulk which ultimately reduces the cost of production and makes it a win-win proposition for all.
- The quality of the final products is maintained as the production process is standardized and well-defined. The processes are mostly automated and high-end machines are used to make the process less prone to human intervention.
- The contract manufacturer does not spend on advertising and marketing like big pharma companies.
- The contactor's capital investment in plant and machinery is not as high as that of large pharma companies.
The Pharmaceutical Contract Manufacturing Process
What is the Pharmaceutical Contract Manufacturing 麻豆原创 Size?
The global CDMO market in 2019 is USD 63.3 billion, including USD 7.03 billion in the clinical stage, USD 44.63 billion in the chemical commercialization stage, and USD 11.66 billion in the biological stage. According to the "Global and China CDMO (Contract Development and Manufacturing Organization) 麻豆原创 Insight Report"听estimate that by 2025, the total size of the global CDMO market will be USD 119.58 billion, with a compound growth rate of 11.2%.
In 2019, the total size of China's CDMO market was 44.1 billion yuan, of which the chemical CDMO scale was 39.22 billion yuan and the bio CDMO scale was 4.88 billion yuan. The research estimates that by 2025, the total size of China's CDMO market will be 131 billion yuan, with a compound growth rate of 19.9%, of which the chemical CDMO scale is 107.86 billion yuan, and the bio CDMO scale is 23.15 billion yuan, with compound growth rates of 18. Overall, China鈥檚 CDMO industry will still maintain rapid growth, among which bio CDMO will grow faster.
听
According to Global Pharmaceutical Contract Manufacturing 麻豆原创 Report global market is expected to reach $120,124.7 million by 2027 growing at a high single-digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth.
The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single-digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.
Who are the Leading Players in Pharmaceutical Contract Manufacturing Industry?
1. Catalent Biologics: Catalent听is a global biologics leader with state-of-the-art facilities in Europe and North America, the company has a wide experience working with customers of all 
sizes from top global multinational pharma to small and virtual companies. Catalent has recently announced the company will manufacture drug substance for AZD1222 at its commercial gene-therapy manufacturing facility in Harmans, MD, and will provide large-scale vial filling and packaging of the vaccine at its facility in Anagni, Italy.
听
sizes from top global multinational pharma to small and virtual companies. Catalent has recently announced the company will manufacture drug substance for AZD1222 at its commercial gene-therapy manufacturing facility in Harmans, MD, and will provide large-scale vial filling and packaging of the vaccine at its facility in Anagni, Italy.听
2. Patheon N.V.: Patheon is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company has head offices in Netherland and US. Thermo Fisher 
Scientific Inc acquired Patheon in 2017.听 The company is currently supporting multiple COVID-19 vaccine programs entering human clinical trials, including monoclonal antibodies (mAbs), nucleic acid-based (mRNA), and plasmids.
听
Scientific Inc acquired Patheon in 2017.听 The company is currently supporting multiple COVID-19 vaccine programs entering human clinical trials, including monoclonal antibodies (mAbs), nucleic acid-based (mRNA), and plasmids.听
3. Piramal Pharma Solutions: Piramal has rich experience in handling complex technology transfers for scale-up batches from customer facilities present across the world. The 
company offers its solutions through a network of facilities located across North America, Europe, and Asia. The company is currently offering the following contract manufacturing services: Starting Materials, Drug Intermediates, APIs, and Finished Dosage Forms.
听
company offers its solutions through a network of facilities located across North America, Europe, and Asia. The company is currently offering the following contract manufacturing services: Starting Materials, Drug Intermediates, APIs, and Finished Dosage Forms.听
4. Lonza: Lonza Pharma & Biotech offers contract development and manufacturing services that enable biotech and pharma companies to bring large and small 
molecule medicines to patients in need. On June 2, 2021, Lonza and Moderna announced that they are moving ahead with their collaboration and extend the drug substance manufacturing of Moderna鈥檚 COVID-19 vaccine with the addition of a new manufacturing line at Lonza鈥檚 Geleen, Netherlands, site.
听
molecule medicines to patients in need. On June 2, 2021, Lonza and Moderna announced that they are moving ahead with their collaboration and extend the drug substance manufacturing of Moderna鈥檚 COVID-19 vaccine with the addition of a new manufacturing line at Lonza鈥檚 Geleen, Netherlands, site.听
5. Aenova Holding GmbH: Aenova is a worldwide leading contract manufacturer for the pharmaceutical and healthcare industry. With 15 production sites in Europe and the USA, the 
Aenova Group offers a broad range of dosage forms for Pharmaceutical and Consumer Health products. With an investment volume of more than 鈧�16 million, Aenova Group is currently building a new sterile production area at its site in Latina to expand its fill and finish capacity for the production of biologics and especially BSL1 and BSL2 vaccines against the SARS-CoV-2 virus.
听
Aenova Group offers a broad range of dosage forms for Pharmaceutical and Consumer Health products. With an investment volume of more than 鈧�16 million, Aenova Group is currently building a new sterile production area at its site in Latina to expand its fill and finish capacity for the production of biologics and especially BSL1 and BSL2 vaccines against the SARS-CoV-2 virus.听
6. Jubilant Pharma Limited: Jubilant Pharma is a subsidiary of Jubilant Pharmova Limited is an integrated contract manufacturer of sterile injectables, 
ophthalmics, optics, and ointments (sterile and non-sterile), creams, and liquids. The company recently announced the development of a novel oral formulation of Remdesivir with the successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers. The company's facilities in North America provide specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Remdesivir is the first and most sought anti-viral drug approved by the US FDA for the treatment of patients with COVID-19 requiring hospitalization.
听
ophthalmics, optics, and ointments (sterile and non-sterile), creams, and liquids. The company recently announced the development of a novel oral formulation of Remdesivir with the successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers. The company's facilities in North America provide specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Remdesivir is the first and most sought anti-viral drug approved by the US FDA for the treatment of patients with COVID-19 requiring hospitalization.听
7. Famar: Famar is a European Contract Manufacturing and Development partner, for the Pharmaceutical and Healthcare industry. Famar 
is providing services for the development and production of pharmaceutical and health care products (CDMO). Famar has 6 production centers and 2 R&D units for pharmaceuticals, medical devices, and health care products in Greece, Italy, and Spain. It produces annually 1700 unique product codes for more than 120 clients
听
is providing services for the development and production of pharmaceutical and health care products (CDMO). Famar has 6 production centers and 2 R&D units for pharmaceuticals, medical devices, and health care products in Greece, Italy, and Spain. It produces annually 1700 unique product codes for more than 120 clients听
**This list is not exhaustive, but is a partial representation of contract manufacturers. The numbers do not necessarily represent a company's ranking in the industry. The exact numbers such as manufacturing capacity, plant locations, and market share information are covered in the premium reports available from 麻豆原创ResearchReports.com
听
听
##The above information have been taken from reports advertised on 麻豆原创ResearchReports.com, Company Websites, and Official Press Releases
Email a colleague
Printer version
Send by email
听
About The Author
Sudeep Chakravarty
